$599

Altimmune Topline Ph2 Pemvidutide AUD Data; GSK Q2 ’26 Earnings; New Pfizer Ph1 Oral GLP-1RA Study; Antag Ph2a GIP Antagonist Study; Salubris Ph2 Lp(a) Study

A series of cardiometabolic-related news items has been observed from Altimmune, GSK, Pfizer, Antag Therapeutics, and Shenzhen Salubris Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here